-
Cardiovascular disease (CVD) is a complex group of heart-related conditions that are the leading cause of death among Americans and Europeans.
-
Acupressure is a therapeutic intervention that has its roots in Traditional Chinese Medicine (TCM) and is based on the same meridian theory used in acupuncture. However, rather than using needles, acupoints are typically stimulated using pressure from fingers, hands, elbows or, in some cases, by devices.
-
A systematic review of 29 studies using vitamin C to help lower blood pressure showed a slightly positive effect, though of debatable clinical value. The study highlights the variable nature of existing data in this realm with regards to quality and methodology.
-
Two large, well-known, U.S. prospective cohort studies, the Nurses' Health Study and the Health Professionals Follow-up Study, evaluated both sugar-sweetened and diet (low-calorie, also called artificially sweetened) soda consumption over 20 years and found one or more daily servings to be associated with a significantly higher risk of stroke.
-
The first retinoid as a topical foam has been approved by the FDA for the treatment of acne. Tazarotene is a synthetic, third-generation, polyaromatic, prodrug that binds to the retinoic acid receptors. Tazarotene is available in both gel and cream formulations. The foam is marketed by Stiefel as Fabior™.
-
The lifetime risk of cardiovascular disease is strongly influenced by risk factor burden and may be similar across race and birth cohorts.
-
Scenario: Interpret the lead MCL-1 rhythm strip shown above. Can you explain the irregularity?
-
A retrospective survey of 744 Dutch and Belgian travelers who had ventured to 2500 m (8200 feet) or higher revealed that 25% developed acute mountain sickness. Only half of this group had followed pre-travel advice regarding altitude sickness, and few took preventive acetazolamide.
-
Rapid influenza diagnostic tests have modest sensitivity and high specificity.
-
The FDA has approved an extended-release, once-daily, dipeptidyl-4 (DPP-4) inhibitor in combination with metformin for adults with type 2 diabetes. Janumet XR combines sitagliptin and metformin. The new combination is the second such product joining Kombiglyze XR, which combines saxagliptin and metformin. Janumet XR is marketed by Merck & Co., Inc.
